Senseonics (NYSE:SENS) Stock Price Up 3.9% – Time to Buy?

Senseonics Holdings, Inc. (NYSE:SENS)’s stock price traded up 3.9% during trading on Thursday . The company traded as high as $7.68 and last traded at $7.51. 318,645 shares changed hands during trading, a decline of 26% from the average session volume of 432,989 shares. The stock had previously closed at $7.23.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SENS. TD Cowen reaffirmed a “buy” rating on shares of Senseonics in a research report on Thursday, January 8th. HC Wainwright increased their price target on Senseonics to $18.50 and gave the company a “buy” rating in a research note on Thursday, November 6th. Barclays restated an “overweight” rating and set a $31.00 price objective (up from $1.50) on shares of Senseonics in a research report on Wednesday, November 5th. Finally, Stifel Nicolaus started coverage on Senseonics in a report on Tuesday, October 21st. They issued a “hold” rating and a $9.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $22.70.

Senseonics Stock Performance

The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The stock has a fifty day simple moving average of $6.41 and a two-hundred day simple moving average of $8.10. The firm has a market capitalization of $306.85 million, a P/E ratio of -57.77 and a beta of 0.63.

Insider Buying and Selling

In related news, Director Douglas A. Roeder bought 15,000 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were acquired at an average cost of $5.83 per share, with a total value of $87,450.00. Following the completion of the purchase, the director directly owned 99,727 shares in the company, valued at $581,408.41. The trade was a 17.70% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Frederick T. Sullivan purchased 5,415 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was bought at an average cost of $5.88 per share, with a total value of $31,840.20. Following the completion of the purchase, the chief financial officer owned 157,028 shares of the company’s stock, valued at approximately $923,324.64. This represents a 3.57% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 30,415 shares of company stock valued at $184,790 over the last ninety days. 3.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Smith Salley Wealth Management increased its position in shares of Senseonics by 10.9% during the third quarter. Smith Salley Wealth Management now owns 61,000 shares of the company’s stock valued at $27,000 after acquiring an additional 6,000 shares during the last quarter. Elite Life Management LLC bought a new position in Senseonics in the 2nd quarter valued at $36,000. HBK Sorce Advisory LLC purchased a new stake in shares of Senseonics during the 3rd quarter valued at $39,000. Ausdal Financial Partners Inc. raised its stake in shares of Senseonics by 50.0% during the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock worth $46,000 after purchasing an additional 35,000 shares during the period. Finally, Goldstone Financial Group LLC purchased a new position in shares of Senseonics in the 3rd quarter worth about $52,000. Hedge funds and other institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.